ATC Group: G03GA Gonadotropins

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G03GA in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G03 Sex hormones and modulators of the genital system
3 G03G Gonadotropins and other ovulation stimulants
4 G03GA Gonadotropins

Group G03GA contents

Code Title
G03GA01 Chorionic gonadotrophin
G03GA02 Human menopausal gonadotrophin
G03GA03 Serum gonadotrophin
G03GA04 Urofollitropin
G03GA05 Follitropin alfa
G03GA06 Follitropin beta
G03GA07 Lutropin alfa
G03GA08 Choriogonadotropin alfa
G03GA09 Corifollitropin alfa
G03GA10
G03GA30 Combinations

Active ingredients in G03GA

Active Ingredient

The principal pharmacodynamic activity in women is oocyte meiosis resumption, follicular rupture (ovulation), corpus luteum formation and production of progesterone and estradiol by the corpus luteum.

Human chorionic gonadotrophin stimulates the steroidogenesis in the gonads by virtue of a biological effect similar to that of LH (Luteinizing hormone, which is the same as interstitial cell stimulating hormone).

Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as (rec)FSH, but with a markedly prolonged duration of FSH activity. Corifollitropin alfa does not display any intrinsic LH/hCG activity.

In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.

Follitropin beta is a recombinant FSH. Follitropin beta can be used to stimulate follicular development and steroid production in selected cases of disturbed gonadal function. Furthermore follitropin beta can be used to promote multiple follicular development in medically assisted reproduction programs.

Follitropin delta is a recombinant human FSH used for controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART). Because follitropin delta is produced in the human cell line PER.C6, the glycosylation profile is different from follitropin alfa and follitropin beta.

Lutropin alfa is a recombinant human Luteinising Hormone (r-hLH). Luteinising Hormone (LH) binds on the ovarian theca (and granulosa) cells and testicular Leydig cells, to a receptor shared with human chorionic gonadotropin hormone (hCG). Lutropin alfa in association with a Follicle Stimulating Hormone (FSH) preparation is recommended for the stimulation of follicular development in adult women with severe Luteinising Hormone (LH) and FSH deficiency.

Urofollitropin contains a highly purified preparation of urinary FSH extracted from the urine of postmenopausal women. FSH stimulates ovarian follicular growth and development as well as gonadal steroid production in women who do not have primary ovarian failure.

Related product monographs

Document Type Information Source  
 BRAVELLE Powder and solvent for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ELONVA Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 FOSTIMON Powder and solvent for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 LUVERIS Powder and solvent for solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 OVALEAP Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 OVIDREL Solution for injection MPI, US: SPL/Old FDA, National Drug Code (US)
 OVITRELLE Solution for injection in pre-filled syringe MPI, EU: SmPC European Medicines Agency (EU)
 PREGNYL 5000IU Powder for solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 PUREGON Solution for injection MPI, EU: SmPC European Medicines Agency (EU)
 REKOVELLE Solution for injection MPI, EU: SmPC European Medicines Agency (EU)